InfuSystem Holdings, IncINFU

Inevitably, the headline from InfuSystem Holdings’ first-quarter 2026 numbers is the same as last quarter’s: revenue fell 3% year-on-year to $33.7 million, a gentle slide that still leaves the group with one of the clearer cash-generating stories in the US med-tech distributor space. Net income of $1.0 million and diluted EPS of $0.05 tell a business that is profitable but not flush, while adjusted EBITDA of $6.4 million sits on slides that still frame the firm as a growth rocket ship. (source: InfuSystem Announces Financial Results for First Quarter 2026, https://ir.infusystem.com/news-events/press-releases/detail/1401/infusystem-announces-financial-results-for-first-quarter)

What the business actually does is simpler: it stocks infusion pumps, disposable administration sets, advanced wound-care gels, and the technicians who keep the kit running. The biomedical-services arm promises depot and onsite repair so hospitals do not have to stockpile spares; the disposable-products range spans pump tubing, PPE, needles, catheters, and closed-system transfer devices; the wound-care line includes BIAKŌS cleansers and biofilm disrupters. (source: InfuSystem Biomedical Services | Onsite & Depot Support | InfuSystem.com, http://www.infusystem.com/biomedical-services; High-Quality Disposable Products | Infusion Pumps | Infusystem.com, http://www.infusystem.com/disposable-products; Advanced Wound Care Products | InfuSystem, http://www.infusystem.com/wound-care/advanced-wound-care-products)

The 10-Q for the quarter ending 31 March 2026 shows total assets of $98.7 million against liabilities of $39.9 million, leaving shareholders’ equity of $58.7 million. Operating cash flow clocked $970,000 for the period, capex was a modest $157,000, and inventory crept up $203,000 to $5.8 million. Cash itself stood at $2.1 million, giving the company a slender liquidity cushion in an environment where med-tech distributors routinely extend 60- to 90-day payment terms to providers. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1337013/000162828026036710/xslF345X06/wk-form4_1779241725.xml)

For anyone hunting a chart, the file rails on the company’s SEC submission index and company-facts JSON; TradingView users can load the ticker INFU (Nasdaq) to see the post-earnings drift. The rail itself carries no market-level commentary, only the raw price and volume history that any user can overlay with their own indicators. (source: SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1337013; SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001337013.json)

The revenue dip is explicitly tied to a single large biomedical-services contract that shrank by $1.6 million in annualised run-rate, a detail the company flagged when it guided the market to a full-year revenue reduction of $7.1 million. Wound-care sales, meanwhile, enjoyed a small lift from two new supplier relationships introduced late in 2025; the revenue uplift is visible in product lines but not yet large enough to offset the contract headwind. (source: InfuSystem Announces Financial Results for First Quarter 2026, https://ir.infusystem.com/news-events/press-releases/detail/1401/infusystem-announces-financial-results-for-first-quarter)

The numbers, in other words, tell a company that is operationally clean, profitable at the bottom line, and still capable of producing cash, but not one that is growing, diversifying quickly, or flush with liquidity. The slide deck remains glossy; the 10-Q is prosaic. The gap between the two is where the real story lives. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1337013/000162828026036709/xslF345X06/wk-form4_1779241719.xml)